Artelo Biosciences to Participate in Major Investment Conference
Artelo Biosciences, Inc. (Nasdaq: ARTL) is preparing to showcase its innovative therapeutics at the H.C. Wainwright 26th Annual Global Investment Conference. This significant event will be held from September 9 to 11, 2024, at the renowned Lotte New York Palace Hotel.
Key Speaker Announcement
The company's CEO, Gregory D. Gorgas, will represent Artelo at the conference. His involvement highlights Artelo's dedication to engaging with investors and demonstrating the progress made in their clinical-stage pharmaceutical programs, which focus on addressing serious health challenges such as cancer, pain, and neurological disorders.
Availability of Presentation
Registered attendees will have the opportunity to view the presentation on-demand starting September 9, 2024. This feature enables investors and stakeholders to access vital information about Artelo's advancements at their own convenience. They can also watch the webcast of the presentation through Artelo’s official channels.
Connecting with Investors
During the conference, the management team will conduct one-on-one meetings with qualified investors. This initiative facilitates personal interactions and provides a platform for addressing any questions regarding Artelo’s innovative strategies in the pharmaceutical sector. Those interested in scheduling a meeting can contact the company directly via its investor relations email.
About Artelo Biosciences
Artelo Biosciences was founded with the goal of developing state-of-the-art treatments. The company focuses on lipid-signaling pathways that are crucial in various medical conditions, including anorexia, anxiety, inflammation, and skin disorders. Artelo's team consists of experienced biopharmaceutical professionals who collaborate closely with researchers to create effective therapeutic solutions that address significant healthcare needs.
Ongoing Research and Development
The company's portfolio features product candidates aimed at tackling serious health issues. With a proactive stance on scientific research, adherence to regulatory standards, and strategic commercial planning, Artelo strives to introduce impactful therapies that address conditions often seen as inadequately treated.
Investor Relations and Contact Information
For further insights into Artelo's strategic initiatives, investors can visit the company's website or connect through social media. The dedicated investor relations team is available to assist with any inquiries, ensuring transparent communication with stakeholders.
Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: ARTL@crescendo-ir.com
Frequently Asked Questions
What is the focus of Artelo Biosciences?
Artelo Biosciences is dedicated to developing treatments for conditions such as cancer, pain syndromes, and dermatological issues by modulating lipid-signaling pathways.
Who will represent Artelo at the conference?
Gregory D. Gorgas, the CEO, will be the primary representative for Artelo at the H.C. Wainwright Conference.
Is the presentation available for all attendees?
Yes, the presentation will be accessible on-demand to all registered attendees starting September 9, 2024.
How can I request a one-on-one meeting with Artelo?
Interested individuals can request meetings through the investor relations email provided by Artelo.
Where can I find more information about Artelo?
More information is available on Artelo’s official website and their Twitter page under @ArteloBio.
